Pearl Steinzor

Few adults with diabetes in Mexico achieve combined CVD risk factor control, highlighting gaps in blood pressure, cholesterol, and glycemic management.

Initiating SGLT2is was linked to lower risks of chronic kidney disease and fewer acute kidney injury events than GLP-1 RAs in metformin-treated type 2 diabetes.

The new Horizon1000 partnership aims to deploy AI tools across 1000 clinics to boost care, support health workers, and address aid cuts in African health systems by 2028.

A new bipartisan funding bill funds key departments ahead of the deadline in an effort to avoid another government shutdown.

As clinical trial activity accelerates and trial designs grow more complex, new data highlight persistent challenges with feasibility, enrollment, and early termination.

Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.

Adults with hypertrophic cardiomyopathy living in lower-income or more socially deprived areas experienced significantly higher risks of heart failure, arrhythmias, stroke, and death.

Black adolescents from lower-income households who engage in volunteer activities experience reduced odds of developing diabetes in adulthood.

Aleata Postell discusses CenterWell Pharmacy's partnership with Eli Lilly to dispense FDA-approved obesity management drugs.

Presenters shared their personal highlights of attending ASCO GI 2026.

Adults with hypertension who have prediabetes and subclinical myocardial injury or stress face a higher risk of incident heart failure, a study suggests.

Jo Varshney, PhD, DVM, discusses how VeriSIM Life’s innovative approach leverages artificial intelligence and multispecies data.

Among patients who did receive early DNAR orders, survival to hospital discharge did not differ by race or ethnicity.

Recent findings support the use of EHRs not only for individual patient care but also for family-centered interventions to curb the growing diabetes epidemic.

Amivantamab-vmjw combined with FOLFOX/FOLFIRI delivers encouraging response rates, durable benefit, and manageable safety.

In an interview during ASH 2025, Ontada's Ira Zackon, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.

Dani Castillo, MD, sheds light on the evolving landscape of first-line therapy in advanced gastric cancer.

Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver metastases.

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal approaches.

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC.

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.

Enrique Velazquez Villarreal, MD, PhD, MPH, MS, reveals how AI is being used to identify early-onset CRC and enhance precision oncology.

Dietary guidelines recommend more whole foods and protein while reducing added sugar and highly processed foods for healthier eating.

As the CDC shifts childhood vaccines to shared decision-making, new surveys show many Americans misunderstand what the policy means—and who it involves.

A study shows falling CRLM incidence and improved survival for synchronous disease, with persistent gaps for metachronous metastases.

A validated XGBoost model identifies psoriasis patients at high hyperglycemia risk, supporting personalized care through a user-friendly web calculator.

From home-based monitoring and subcutaneous immunotherapy to expanded community cancer networks, 2025 marked a pivotal year in rethinking how cancer care is delivered.

From cutting-edge AI detection tools to rising incidence in younger adults and threats to free screenings, 2025 brought major shifts in the struggle against colorectal cancer.

Leadership shakeups at the CDC, legal challenges, and growing scrutiny of the childhood immunization schedule have disrupted US vaccine policy.

Experts discuss the evolution, challenges, and next steps for value-based oncology payment models.